CYP2D6 & CYP2C19 genotyping panel

From Aaushi

Jump to navigation Jump to search

^[1]

Indications

evaluation of patients for amitriptyline therapy

Clinical significance

CPIC recommends alternative drug to amitrityline for CYP2D6 or CYP2C19 ultrarapid metabolizers & for CYP2D6 poor metabolizers^[1]

More general terms

chemistry panel

Components

References

↑ ^1.0 ^1.1 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline information for amitriptyline and CYP2C19, CYP2D6. https://www.pharmgkb.org/guideline/PA166105006

Retrieved from "https://aaushi.info/w/index.php?title=A397416&oldid=947151"

↑ Back to top